Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Poul Strange"'
Autor:
George Grunberger, Cheryl R. Rosenfeld, Bruce W. Bode, Scott D. Abbott, Carla Nikkel, Leon Shi, Poul Strange
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Abstract Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia ris
Externí odkaz:
https://doaj.org/article/28f840a6feea4b70b5b2d5296aef74f3
Autor:
Mark J. Cziraky, Scott Abbott, Matt Nguyen, Kay Larholt, Elizabeth Apgar, Thomas Wasser, Poul Strange, Leon Shi, H. Courtenay Harrison, Beverly Everitt, Lynn Nowak
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 6, Iss 2 (2019)
**Background:** Many patients with type 2 diabetes mellitus (T2DM) do not have adequate glycemic control, leading to poor patient outcomes and high healthcare costs. **Objective:** This prospective pragmatic clinical trial evaluated V-Go, a wearable
Externí odkaz:
https://doaj.org/article/89733cc7314a40b3b3e424271cbbcd12
Autor:
Jasmin R. Kastner, Timothy S. Bailey, Poul Strange, Leon Shi, Keith A. Oberg, Paul J. Strasma, Jeffrey I. Joseph, Douglas B. Muchmore
Publikováno v:
Diabetes Technology & Therapeutics. 25:143-147
Autor:
Jasmin R. Kastner, Nisha Venkatesh, Katie Brown, Douglas B. Muchmore, Elif Ekinci, Spiros Fourlanos, Jeffrey I Joseph, Miami Shafeeq, Leon Shi, Poul Strange, Paul J. Strasma, David N. O'Neal
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1143-1149
To assess the feasibility of a prototype insulin infusion set (IIS) for extended wear in adults with type 1 diabetes.The prototype Capillary Biomedical investigational extended-wear IIS (CBX IIS) incorporates a soft, flexible, reinforced kink-resista
Autor:
Jasmin Renée, Kastner, Timothy S, Bailey, Poul, Strange, Leon, Shi, Keith A, Oberg, Paul, Strasma, Jeffrey I, Joseph, Douglas B, Muchmore
Publikováno v:
Diabetes technologytherapeutics.
Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report pharmacodynamic (PD) and pharmacokinetic (PK) data extending these observations to 7 da
Autor:
TIMOTHY S. BAILEY, JASMIN R. KASTNER, POUL STRANGE, LEI SHI, KEITH A. OBERG, JEFFREY I. JOSEPH, PAUL J. STRASMA, DOUGLAS B. MUCHMORE
Publikováno v:
Diabetes. 71
Insulin exposure and action are known to differ on each of 3 days of infusion set wear during CSII. We extend these observations to 1 week in a pilot phase study comparing conventional Teflon angled infusion sets to a prototype extended wear set usin
Autor:
R. Loch Macdonald, Daniel Hänggi, Poul Strange, Hans Jakob Steiger, J Mocco, Michael Miller, Stephan A. Mayer, Brian L. Hoh, Herbert J. Faleck, Nima Etminan, Michael N. Diringer, Andrew P. Carlson, Francois Aldrich
Publikováno v:
Journal of Neurosurgery. 134:95-101
OBJECTIVEThe objective of this study was to measure the concentration of nimodipine in CSF and plasma after intraventricular injection of a sustained-release formulation of nimodipine (EG-1962) in patients with aneurysmal subarachnoid hemorrhage (SAH
Autor:
null Jasmin R. Kastner, null Nisha Venkatesh, null Katie Brown, null Douglas B. Muchmore, null Elif Ekinci, null Spiros Fourlanos, null Jeffrey I Joseph, null Miami Shafeeq, null Leon Shi, null Poul Strange, null Paul J. Strasma, null David N. O’Neal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2623334936b66c066894d48155d69614
https://doi.org/10.1111/dom.14685/v3/response1
https://doi.org/10.1111/dom.14685/v3/response1
Autor:
Cheryl R. Rosenfeld, Poul Strange, Bruce W. Bode, Carla Nikkel, George Grunberger, Scott D. Abbott, Leon Shi
Publikováno v:
Drugs-Real World Outcomes
Drugs-Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Drugs-Real World Outcomes, Vol 7, Iss 1, Pp 31-40 (2019)
Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in pati
Autor:
H. Courtenay Harrison, Leon Shi, Mark J. Cziraky, Matt Nguyen, Scott D Abbott, T. Wasser, Lynn Nowak, Beverly Everitt, Elizabeth Apgar, Kay Larholt, Poul Strange
Publikováno v:
Journal of Health Economics and Outcomes Research
Background: Many patients with type 2 diabetes mellitus (T2DM) do not have adequate glycemic control, leading to poor patient outcomes and high healthcare costs. Objective: This prospective pragmatic clinical trial evaluated V-Go, a wearable insulin